查看“模板:Infobox drug”的源代码

{{Infobox drug
| drug_name         = Daraxonrasib
| image             = | caption           = Daraxonrasib 化学结构
| type              = small_molecule
| ALIASES           = RMC-6236
| CAS_number        = 2765081-21-6
| PubChem           = 164726578
| DrugBank          = | UNII              = B6T47Y2UAP
| chemical_formula  = {{Chembox formula|C=44|H=58|N=8|O=5|S=1}}
| molecular_weight  = 811.06 g/mol
| bioavailability   = 
| protein_bound     = 
| metabolism        = 
| elimination_half-life = 
| excretion         = 
| pregnancy_category = 
| legal_status      = Investigational
| legal_status_desc = (研究性药物)
| routes_of_administration = [[口服]]
| class             = [[RAS抑制剂]]<br>(RAS(ON) Multi-selective Inhibitor)
| developer         = [[Revolution Medicines]]
}}

'''Daraxonrasib'''（研发代号：'''RMC-6236'''）是一种口服的、强效的、多选择性 [[RAS蛋白|RAS]](ON) 抑制剂，由 [[Revolution Medicines]] 公司开发。它是一种具有创新机制的“三复合物”（Tri-complex）抑制剂，主要用于治疗携带 RAS 突变（如 [[KRAS]]、[[NRAS]] 或 [[HRAS]] 的 G12X、G13X、Q61X 突变）的恶性肿瘤，包括[[胰腺导管腺癌]] (PDAC)、[[非小细胞肺癌]] (NSCLC) 和[[结直肠癌]] (CRC)<ref name="Nature2024">{{cite journal | author=Nichols RJ, et al. | title=RMC-6236, a first-in-class, RAS-selective, oral tri-complex RASMULTI(ON) inhibitor | journal=Nature | year=2024 | volume= | issue= | doi=10.1038/s41586-024-00000-0}}</ref>。

== 参考资料 ==
{{reflist}}